-
(
GinsbergGMLauerJAZelleS, et al. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan Africa and South East Asia: mathematical modelling study. BMJ
2012; 344: e614.)
GinsbergGMLauerJAZelleS, et al. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan Africa and South East Asia: mathematical modelling study. BMJ
2012; 344: e614.
GinsbergGMLauerJAZelleS, et al. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan Africa and South East Asia: mathematical modelling study. BMJ
2012; 344: e614.,
GinsbergGMLauerJAZelleS, et al. Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan Africa and South East Asia: mathematical modelling study. BMJ
2012; 344: e614.
-
(
JiangXTangHChenT. Epidemiology of gynecologic cancers in China. J Gynecol Oncol
2018; 29: e7.)
JiangXTangHChenT. Epidemiology of gynecologic cancers in China. J Gynecol Oncol
2018; 29: e7.
JiangXTangHChenT. Epidemiology of gynecologic cancers in China. J Gynecol Oncol
2018; 29: e7.,
JiangXTangHChenT. Epidemiology of gynecologic cancers in China. J Gynecol Oncol
2018; 29: e7.
-
Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy demonstration project in Argentina: a population-based, before-and-after retrospective cohort study
-
Human papillomavirus testing in the prevention of cervical cancer
-
(
MassadLSEinsteinMHHuhWK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol
2013; 121: 829–846.23635684)
MassadLSEinsteinMHHuhWK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol
2013; 121: 829–846.23635684
MassadLSEinsteinMHHuhWK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol
2013; 121: 829–846.23635684,
MassadLSEinsteinMHHuhWK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol
2013; 121: 829–846.23635684
-
(
ArrossiSPaolinoMLaudiR, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy demonstration project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Health
2019; 7: e772–e783.)
ArrossiSPaolinoMLaudiR, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy demonstration project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Health
2019; 7: e772–e783.
ArrossiSPaolinoMLaudiR, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy demonstration project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Health
2019; 7: e772–e783.,
ArrossiSPaolinoMLaudiR, et al. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy demonstration project in Argentina: a population-based, before-and-after retrospective cohort study. Lancet Glob Health
2019; 7: e772–e783.
-
Relative performance of HPV and cytology components of co-testing in cervical screening
-
(
HuhWKAultKAChelmowD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol
2015; 136: 178–182.25579107)
HuhWKAultKAChelmowD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol
2015; 136: 178–182.25579107
HuhWKAultKAChelmowD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol
2015; 136: 178–182.25579107,
HuhWKAultKAChelmowD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol
2015; 136: 178–182.25579107
-
(
CurrySJKristAHOwensDK, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA
2018; 320: 674–686.30140884)
CurrySJKristAHOwensDK, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA
2018; 320: 674–686.30140884
CurrySJKristAHOwensDK, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA
2018; 320: 674–686.30140884,
CurrySJKristAHOwensDK, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA
2018; 320: 674–686.30140884
-
Cancer attributable to human papillomavirus infection in China: burden and trends
-
Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study
-
Screening for cervical cancer: US preventive services task force recommendation statement
-
Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening
-
Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S
-
(
TuerxunGYukesaierALuL, et al. Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women. Oncologist
2016; 21: 825–831.27317575)
TuerxunGYukesaierALuL, et al. Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women. Oncologist
2016; 21: 825–831.27317575
TuerxunGYukesaierALuL, et al. Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women. Oncologist
2016; 21: 825–831.27317575,
TuerxunGYukesaierALuL, et al. Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women. Oncologist
2016; 21: 825–831.27317575
-
(
SchiffmanMCastlePEJeronimoJ, et al. Human papillomavirus and cervical cancer. Lancet
2007; 370: 890–907.17826171)
SchiffmanMCastlePEJeronimoJ, et al. Human papillomavirus and cervical cancer. Lancet
2007; 370: 890–907.17826171
SchiffmanMCastlePEJeronimoJ, et al. Human papillomavirus and cervical cancer. Lancet
2007; 370: 890–907.17826171,
SchiffmanMCastlePEJeronimoJ, et al. Human papillomavirus and cervical cancer. Lancet
2007; 370: 890–907.17826171
-
(
ReboljMBrentnallARMathewsC, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer
2019; 121: 455–463.31409912)
ReboljMBrentnallARMathewsC, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer
2019; 121: 455–463.31409912
ReboljMBrentnallARMathewsC, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer
2019; 121: 455–463.31409912,
ReboljMBrentnallARMathewsC, et al. 16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer
2019; 121: 455–463.31409912
-
Educational attainment and mortality: results from the sixth population census in China
-
(
CastlePEWheelerCMCamposNG, et al. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med
2018; 111: 177–179.29548787)
CastlePEWheelerCMCamposNG, et al. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med
2018; 111: 177–179.29548787
CastlePEWheelerCMCamposNG, et al. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med
2018; 111: 177–179.29548787,
CastlePEWheelerCMCamposNG, et al. Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med
2018; 111: 177–179.29548787
-
(
TougherSDuttVPereiraS, et al. Effect of a multifaceted social franchising model on quality and coverage of maternal, newborn, and reproductive health-care services in Uttar Pradesh, India: a quasi-experimental study. Lancet Glob Health
2018; 6: e211–e221.)
TougherSDuttVPereiraS, et al. Effect of a multifaceted social franchising model on quality and coverage of maternal, newborn, and reproductive health-care services in Uttar Pradesh, India: a quasi-experimental study. Lancet Glob Health
2018; 6: e211–e221.
TougherSDuttVPereiraS, et al. Effect of a multifaceted social franchising model on quality and coverage of maternal, newborn, and reproductive health-care services in Uttar Pradesh, India: a quasi-experimental study. Lancet Glob Health
2018; 6: e211–e221.,
TougherSDuttVPereiraS, et al. Effect of a multifaceted social franchising model on quality and coverage of maternal, newborn, and reproductive health-care services in Uttar Pradesh, India: a quasi-experimental study. Lancet Glob Health
2018; 6: e211–e221.
-
(
SchiffmanMKinneyWKCheungLC, et al. Relative performance of HPV and cytology components of co-testing in cervical screening. J Natl Cancer Inst
2018; 110: 501–508.29145648)
SchiffmanMKinneyWKCheungLC, et al. Relative performance of HPV and cytology components of co-testing in cervical screening. J Natl Cancer Inst
2018; 110: 501–508.29145648
SchiffmanMKinneyWKCheungLC, et al. Relative performance of HPV and cytology components of co-testing in cervical screening. J Natl Cancer Inst
2018; 110: 501–508.29145648,
SchiffmanMKinneyWKCheungLC, et al. Relative performance of HPV and cytology components of co-testing in cervical screening. J Natl Cancer Inst
2018; 110: 501–508.29145648
-
(
CastlePEStolerMHWrightTCJr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol
2011; 12: 880–890.21865084)
CastlePEStolerMHWrightTCJr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol
2011; 12: 880–890.21865084
CastlePEStolerMHWrightTCJr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol
2011; 12: 880–890.21865084,
CastlePEStolerMHWrightTCJr, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol
2011; 12: 880–890.21865084
-
(
SunPSongYRuanG, et al. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. J Gynecol Oncol
2017; 28: e50.)
SunPSongYRuanG, et al. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. J Gynecol Oncol
2017; 28: e50.
SunPSongYRuanG, et al. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. J Gynecol Oncol
2017; 28: e50.,
SunPSongYRuanG, et al. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. J Gynecol Oncol
2017; 28: e50.
-
Role of HPV DNA testing in modern gynaecological practice
-
(
LuoXMSongLWuJL, et al. Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China. Chin J Prev Med
2016; 50: 346–350.)
LuoXMSongLWuJL, et al. Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China. Chin J Prev Med
2016; 50: 346–350.
LuoXMSongLWuJL, et al. Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China. Chin J Prev Med
2016; 50: 346–350.,
LuoXMSongLWuJL, et al. Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China. Chin J Prev Med
2016; 50: 346–350.
-
A review of human carcinogens–part B: biological agents
-
WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer
-
(
HuhWKWilliamsEHuangJ, et al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy
2015; 13: 95–107.25385310)
HuhWKWilliamsEHuangJ, et al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy
2015; 13: 95–107.25385310
HuhWKWilliamsEHuangJ, et al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy
2015; 13: 95–107.25385310,
HuhWKWilliamsEHuangJ, et al. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening. Appl Health Econ Health Policy
2015; 13: 95–107.25385310
-
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
-
(
GlasgowREVogtTMBolesSM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health
1999; 89: 1322–1327.10474547)
GlasgowREVogtTMBolesSM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health
1999; 89: 1322–1327.10474547
GlasgowREVogtTMBolesSM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health
1999; 89: 1322–1327.10474547,
GlasgowREVogtTMBolesSM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health
1999; 89: 1322–1327.10474547
-
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program
-
(
JinXWLipoldLFoucherJ, et al. Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years. J Gen Intern Med
2016; 31: 1338–1344.27418345)
JinXWLipoldLFoucherJ, et al. Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years. J Gen Intern Med
2016; 31: 1338–1344.27418345
JinXWLipoldLFoucherJ, et al. Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years. J Gen Intern Med
2016; 31: 1338–1344.27418345,
JinXWLipoldLFoucherJ, et al. Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years. J Gen Intern Med
2016; 31: 1338–1344.27418345
-
A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women
-
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors
-
(
CrosbieEJEinsteinMHFranceschiS, et al. Human papillomavirus and cervical cancer. Lancet
2013; 382: 889–899.23618600)
CrosbieEJEinsteinMHFranceschiS, et al. Human papillomavirus and cervical cancer. Lancet
2013; 382: 889–899.23618600
CrosbieEJEinsteinMHFranceschiS, et al. Human papillomavirus and cervical cancer. Lancet
2013; 382: 889–899.23618600,
CrosbieEJEinsteinMHFranceschiS, et al. Human papillomavirus and cervical cancer. Lancet
2013; 382: 889–899.23618600
-
(
DongBSunPRuanG, et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res
2018; 10: 4839–4851.30425576)
DongBSunPRuanG, et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res
2018; 10: 4839–4851.30425576
DongBSunPRuanG, et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res
2018; 10: 4839–4851.30425576,
DongBSunPRuanG, et al. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res
2018; 10: 4839–4851.30425576
-
Cancer statistics in China, 2015
-
Human papillomavirus and cervical cancer
-
Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan Africa and South East Asia: mathematical modelling study
-
PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort
-
Cross-sectional study to assess the need to commence opportunistic screening of women for cervical cancer presenting with sexually transmitted disease in Western India
-
(
LewJBSimmsKTSmithMA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. Lancet Public Health
2017; 2: e96–e107.)
LewJBSimmsKTSmithMA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. Lancet Public Health
2017; 2: e96–e107.
LewJBSimmsKTSmithMA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. Lancet Public Health
2017; 2: e96–e107.,
LewJBSimmsKTSmithMA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the national cervical screening program. Lancet Public Health
2017; 2: e96–e107.
-
(
YouensKEHoslerGAWashingtonPJ, et al. Clinical experience with the cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn
2011; 13: 160–166.21354050)
YouensKEHoslerGAWashingtonPJ, et al. Clinical experience with the cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn
2011; 13: 160–166.21354050
YouensKEHoslerGAWashingtonPJ, et al. Clinical experience with the cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn
2011; 13: 160–166.21354050,
YouensKEHoslerGAWashingtonPJ, et al. Clinical experience with the cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn
2011; 13: 160–166.21354050
-
Evaluating the public health impact of health promotion interventions: the RE-AIM framework
-
(
RoncoGGiorgi RossiP. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol
2018; 47: 107–118.28918099)
RoncoGGiorgi RossiP. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol
2018; 47: 107–118.28918099
RoncoGGiorgi RossiP. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol
2018; 47: 107–118.28918099,
RoncoGGiorgi RossiP. Role of HPV DNA testing in modern gynaecological practice. Best Pract Res Clin Obstet Gynaecol
2018; 47: 107–118.28918099
-
The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study
-
Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China
-
Cervical cancer screening among adult women in China, 2010
-
(
ZhouSZouGChenX, et al. Educational attainment and mortality: results from the sixth population census in China. J Glob Health
2019; 9: 020604.31893036)
ZhouSZouGChenX, et al. Educational attainment and mortality: results from the sixth population census in China. J Glob Health
2019; 9: 020604.31893036
ZhouSZouGChenX, et al. Educational attainment and mortality: results from the sixth population census in China. J Glob Health
2019; 9: 020604.31893036,
ZhouSZouGChenX, et al. Educational attainment and mortality: results from the sixth population census in China. J Glob Health
2019; 9: 020604.31893036
-
(
WangBHeMChaoA, et al. Cervical cancer screening among adult women in China, 2010. Oncologist
2015; 20: 627–634.25956407)
WangBHeMChaoA, et al. Cervical cancer screening among adult women in China, 2010. Oncologist
2015; 20: 627–634.25956407
WangBHeMChaoA, et al. Cervical cancer screening among adult women in China, 2010. Oncologist
2015; 20: 627–634.25956407,
WangBHeMChaoA, et al. Cervical cancer screening among adult women in China, 2010. Oncologist
2015; 20: 627–634.25956407
-
16/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot
-
(
World Health Organization. WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer, https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf. (2018, accessed 19 April 2019).)
World Health Organization. WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer, https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf. (2018, accessed 19 April 2019).
World Health Organization. WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer, https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf. (2018, accessed 19 April 2019).,
World Health Organization. WHO director-general calls for all countries to take action to help end the suffering caused by cervical cancer, https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf. (2018, accessed 19 April 2019).
-
(
NaberSKde KokIMMatthijsseSM, et al. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control
2016; 27: 569–581.26970740)
NaberSKde KokIMMatthijsseSM, et al. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control
2016; 27: 569–581.26970740
NaberSKde KokIMMatthijsseSM, et al. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control
2016; 27: 569–581.26970740,
NaberSKde KokIMMatthijsseSM, et al. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control
2016; 27: 569–581.26970740
-
Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay
-
(1997)
American society for colposcopy and cervical pathology.
Journal of lower genital tract disease, 1 2
-
Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis
-
(
KhandkerSRKoolwalGBSamadHA. Handbook on impact evaluation: quantitative methods and practices, http://bit.ly/1d2Ve8m (2010, accessed 19 April 2019).)
KhandkerSRKoolwalGBSamadHA. Handbook on impact evaluation: quantitative methods and practices, http://bit.ly/1d2Ve8m (2010, accessed 19 April 2019).
KhandkerSRKoolwalGBSamadHA. Handbook on impact evaluation: quantitative methods and practices, http://bit.ly/1d2Ve8m (2010, accessed 19 April 2019).,
KhandkerSRKoolwalGBSamadHA. Handbook on impact evaluation: quantitative methods and practices, http://bit.ly/1d2Ve8m (2010, accessed 19 April 2019).
-
Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force
-
Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women
-
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis
-
(
SungYEKiEYLeeYS, et al. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol
2016; 27: e56.)
SungYEKiEYLeeYS, et al. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol
2016; 27: e56.
SungYEKiEYLeeYS, et al. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol
2016; 27: e56.,
SungYEKiEYLeeYS, et al. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol
2016; 27: e56.
-
Epidemiologic classification of human papillomavirus types associated with cervical cancer
-
World Health Organization. WHO directorgeneral calls for all countries to take action to help end the suffering caused by cervical cancer
-
(
SmelovVElfströmKMJohanssonAL, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer
2015; 136: 1171–1180.25043476)
SmelovVElfströmKMJohanssonAL, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer
2015; 136: 1171–1180.25043476
SmelovVElfströmKMJohanssonAL, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer
2015; 136: 1171–1180.25043476,
SmelovVElfströmKMJohanssonAL, et al. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer
2015; 136: 1171–1180.25043476
-
An overview of prevention and early detection of cervical cancers
-
(
SaslowDSolomonDLawsonHW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis
2012; 16: 175–204.22418039)
SaslowDSolomonDLawsonHW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis
2012; 16: 175–204.22418039
SaslowDSolomonDLawsonHW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis
2012; 16: 175–204.22418039,
SaslowDSolomonDLawsonHW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis
2012; 16: 175–204.22418039
-
Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population
-
Developing the terminology for dissemination and implementation research
-
(
MuñozNBoschFXde SanjoséS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med
2003; 348: 518–527.12571259)
MuñozNBoschFXde SanjoséS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med
2003; 348: 518–527.12571259
MuñozNBoschFXde SanjoséS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med
2003; 348: 518–527.12571259,
MuñozNBoschFXde SanjoséS, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med
2003; 348: 518–527.12571259
-
Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China
-
Organization and evaluation of a pilot cervical cancer screening program in Morocco
-
(
WangRGuoXLWismanGB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis
2015; 15: 257.26142044)
WangRGuoXLWismanGB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis
2015; 15: 257.26142044
WangRGuoXLWismanGB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis
2015; 15: 257.26142044,
WangRGuoXLWismanGB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis
2015; 15: 257.26142044
-
(
AlamedaFGarroteLMojalS, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med
2015; 139: 241–244.25611107)
AlamedaFGarroteLMojalS, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med
2015; 139: 241–244.25611107
AlamedaFGarroteLMojalS, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med
2015; 139: 241–244.25611107,
AlamedaFGarroteLMojalS, et al. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. Arch Pathol Lab Med
2015; 139: 241–244.25611107
-
(
MezeiAKArmstrongHLPedersenHN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer
2017; 141: 437–446.28297074)
MezeiAKArmstrongHLPedersenHN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer
2017; 141: 437–446.28297074
MezeiAKArmstrongHLPedersenHN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer
2017; 141: 437–446.28297074,
MezeiAKArmstrongHLPedersenHN, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer
2017; 141: 437–446.28297074
-
Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real-time PCR and the PCR-reverse dot blot assays
-
(
LeiJPlonerALaghedenC, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med
2018; 15: e1002666.)
LeiJPlonerALaghedenC, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med
2018; 15: e1002666.
LeiJPlonerALaghedenC, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med
2018; 15: e1002666.,
LeiJPlonerALaghedenC, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med
2018; 15: e1002666.
-
(
KoshiolJLindsayLPimentaJM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol
2008; 168: 123–137.18483125)
KoshiolJLindsayLPimentaJM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol
2008; 168: 123–137.18483125
KoshiolJLindsayLPimentaJM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol
2008; 168: 123–137.18483125,
KoshiolJLindsayLPimentaJM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol
2008; 168: 123–137.18483125
-
(
LuYLiPLuoG, et al. Cancer attributable to human papillomavirus infection in China: burden and trends. Cancer
2020; 126: 3719–3732.32484937)
LuYLiPLuoG, et al. Cancer attributable to human papillomavirus infection in China: burden and trends. Cancer
2020; 126: 3719–3732.32484937
LuYLiPLuoG, et al. Cancer attributable to human papillomavirus infection in China: burden and trends. Cancer
2020; 126: 3719–3732.32484937,
LuYLiPLuoG, et al. Cancer attributable to human papillomavirus infection in China: burden and trends. Cancer
2020; 126: 3719–3732.32484937
-
(
RuanGSongYDongB, et al. Cervical cancer screening using the cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Manag Res
2018; 10: 3227–3235.30233239)
RuanGSongYDongB, et al. Cervical cancer screening using the cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Manag Res
2018; 10: 3227–3235.30233239
RuanGSongYDongB, et al. Cervical cancer screening using the cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Manag Res
2018; 10: 3227–3235.30233239,
RuanGSongYDongB, et al. Cervical cancer screening using the cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China. Cancer Manag Res
2018; 10: 3227–3235.30233239
-
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance
-
Handbook on impact evaluation: quantitative methods and practices
-
(
RupaniMPPawarABBansalRK, et al. Cross-sectional study to assess the need to commence opportunistic screening of women for cervical cancer presenting with sexually transmitted disease in Western India. Eur J Cancer Care (Engl). Epub ahead of print 22 December 2016. DOI: 10.1111/ecc.12626.)
RupaniMPPawarABBansalRK, et al. Cross-sectional study to assess the need to commence opportunistic screening of women for cervical cancer presenting with sexually transmitted disease in Western India. Eur J Cancer Care (Engl). Epub ahead of print 22 December 2016. DOI: 10.1111/ecc.12626.
RupaniMPPawarABBansalRK, et al. Cross-sectional study to assess the need to commence opportunistic screening of women for cervical cancer presenting with sexually transmitted disease in Western India. Eur J Cancer Care (Engl). Epub ahead of print 22 December 2016. DOI: 10.1111/ecc.12626.,
RupaniMPPawarABBansalRK, et al. Cross-sectional study to assess the need to commence opportunistic screening of women for cervical cancer presenting with sexually transmitted disease in Western India. Eur J Cancer Care (Engl). Epub ahead of print 22 December 2016. DOI: 10.1111/ecc.12626.
-
(
BouvardVBaanRStraifK, et al. A review of human carcinogens–part B: biological agents. Lancet Oncol
2009; 10: 321–322.19350698)
BouvardVBaanRStraifK, et al. A review of human carcinogens–part B: biological agents. Lancet Oncol
2009; 10: 321–322.19350698
BouvardVBaanRStraifK, et al. A review of human carcinogens–part B: biological agents. Lancet Oncol
2009; 10: 321–322.19350698,
BouvardVBaanRStraifK, et al. A review of human carcinogens–part B: biological agents. Lancet Oncol
2009; 10: 321–322.19350698
-
(
MishraGAPimpleSAShastriSS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol
2011; 32: 125–132.22557777)
MishraGAPimpleSAShastriSS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol
2011; 32: 125–132.22557777
MishraGAPimpleSAShastriSS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol
2011; 32: 125–132.22557777,
MishraGAPimpleSAShastriSS. An overview of prevention and early detection of cervical cancers. Indian J Med Paediatr Oncol
2011; 32: 125–132.22557777
-
(2015)
Cancer statistics in China ,
-
(
SchiffmanMWentzensenNWacholderS, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst
2011; 103: 368–383.21282563)
SchiffmanMWentzensenNWacholderS, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst
2011; 103: 368–383.21282563
SchiffmanMWentzensenNWacholderS, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst
2011; 103: 368–383.21282563,
SchiffmanMWentzensenNWacholderS, et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst
2011; 103: 368–383.21282563
-
Cervical cancer screening using the cervista high-risk human papillomavirus test: opportunistic screening of a hospital-based population in Fujian province, China
-
(
FerlayJSoerjomataramIDikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136: E359–E386.)
FerlayJSoerjomataramIDikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136: E359–E386.
FerlayJSoerjomataramIDikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136: E359–E386.,
FerlayJSoerjomataramIDikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer
2015; 136: E359–E386.
-
(
ChenWZhengRBaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin
2016; 66: 115–132.26808342)
ChenWZhengRBaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin
2016; 66: 115–132.26808342
ChenWZhengRBaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin
2016; 66: 115–132.26808342,
ChenWZhengRBaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin
2016; 66: 115–132.26808342
-
Effect of a multifaceted social franchising model on quality and coverage of maternal, newborn, and reproductive health-care services in Uttar Pradesh, India: a quasi-experimental study
-
Epidemiology of gynecologic cancers in China
-
(
RabinBABrownsonRC. Developing the terminology for dissemination and implementation research. In: BrownsonRCColditzGProcterE (eds) Dissemination and implementation research in health. New York: Oxford University Press, 2012, pp.23–54.)
RabinBABrownsonRC. Developing the terminology for dissemination and implementation research. In: BrownsonRCColditzGProcterE (eds) Dissemination and implementation research in health. New York: Oxford University Press, 2012, pp.23–54.
RabinBABrownsonRC. Developing the terminology for dissemination and implementation research. In: BrownsonRCColditzGProcterE (eds) Dissemination and implementation research in health. New York: Oxford University Press, 2012, pp.23–54.,
RabinBABrownsonRC. Developing the terminology for dissemination and implementation research. In: BrownsonRCColditzGProcterE (eds) Dissemination and implementation research in health. New York: Oxford University Press, 2012, pp.23–54.
-
Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial
-
Evaluation of careHPV, cervista human papillomavirus, and hybrid capture 2 methods in diagnosing cervical intraepithelial neoplasia grade 2+ in Xinjiang Uyghur women
-
(
ArbynMXuLVerdoodtF, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med
2017; 166: 118–127.27842420)
ArbynMXuLVerdoodtF, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med
2017; 166: 118–127.27842420
ArbynMXuLVerdoodtF, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med
2017; 166: 118–127.27842420,
ArbynMXuLVerdoodtF, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann Intern Med
2017; 166: 118–127.27842420
-
High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study
-
(
Lazcano-PonceELőrinczATTorresL, et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer
2014; 135: 109–116.24615258)
Lazcano-PonceELőrinczATTorresL, et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer
2014; 135: 109–116.24615258
Lazcano-PonceELőrinczATTorresL, et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer
2014; 135: 109–116.24615258,
Lazcano-PonceELőrinczATTorresL, et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer
2014; 135: 109–116.24615258
-
Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
-
Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review
-
(
ElseEASwoyerRZhangY, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol
2011; 49: 1907–1912.21068278)
ElseEASwoyerRZhangY, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol
2011; 49: 1907–1912.21068278
ElseEASwoyerRZhangY, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol
2011; 49: 1907–1912.21068278,
ElseEASwoyerRZhangY, et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol
2011; 49: 1907–1912.21068278
-
(
KangYSunPMaoX, et al. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. J Gynecol Oncol
2019; 30: e29.)
KangYSunPMaoX, et al. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. J Gynecol Oncol
2019; 30: e29.
KangYSunPMaoX, et al. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. J Gynecol Oncol
2019; 30: e29.,
KangYSunPMaoX, et al. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort. J Gynecol Oncol
2019; 30: e29.
-
(
SelmouniFSauvagetCBelakhelL, et al. Organization and evaluation of a pilot cervical cancer screening program in Morocco. Int J Gynaecol Obstet
2016; 132: 25–28.26434670)
SelmouniFSauvagetCBelakhelL, et al. Organization and evaluation of a pilot cervical cancer screening program in Morocco. Int J Gynaecol Obstet
2016; 132: 25–28.26434670
SelmouniFSauvagetCBelakhelL, et al. Organization and evaluation of a pilot cervical cancer screening program in Morocco. Int J Gynaecol Obstet
2016; 132: 25–28.26434670,
SelmouniFSauvagetCBelakhelL, et al. Organization and evaluation of a pilot cervical cancer screening program in Morocco. Int J Gynaecol Obstet
2016; 132: 25–28.26434670
-
Cost-effectiveness of primary HPV testing, cytology and co-testing as cervical cancer screening for women above age 30 years
-
(
WuQZhaoXFuY, et al. A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. Cancer Med
2017; 6: 1091–1101.28378404)
WuQZhaoXFuY, et al. A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. Cancer Med
2017; 6: 1091–1101.28378404
WuQZhaoXFuY, et al. A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. Cancer Med
2017; 6: 1091–1101.28378404,
WuQZhaoXFuY, et al. A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. Cancer Med
2017; 6: 1091–1101.28378404
-
Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-saharan journals
-
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
-
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study
-
(
ZhangLDaiYChenJ, et al. Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real-time PCR and the PCR-reverse dot blot assays. J Med Virol
2018; 90: 177–183.28851089)
ZhangLDaiYChenJ, et al. Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real-time PCR and the PCR-reverse dot blot assays. J Med Virol
2018; 90: 177–183.28851089
ZhangLDaiYChenJ, et al. Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real-time PCR and the PCR-reverse dot blot assays. J Med Virol
2018; 90: 177–183.28851089,
ZhangLDaiYChenJ, et al. Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real-time PCR and the PCR-reverse dot blot assays. J Med Virol
2018; 90: 177–183.28851089
-
Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study
-
(
MelnikowJHendersonJTBurdaBU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA
2018; 320: 687–705.30140883)
MelnikowJHendersonJTBurdaBU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA
2018; 320: 687–705.30140883
MelnikowJHendersonJTBurdaBU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA
2018; 320: 687–705.30140883,
MelnikowJHendersonJTBurdaBU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA
2018; 320: 687–705.30140883
-
Clinical experience with the cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens
-
(2012)
East Asia: mathematical modelling study